PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 24 No. 12
Pages: 1  2  3  
Previous
 

Treatment Resistance in Youths With ADHD and Comorbid Conditions

By Anthony L. Rostain, MD, MA | October 1, 2007
Dr Rostain is professor of psychiatry and pediatrics, attending child psychiatrist at the Children's Hospital of Philadelphia, and medical director of the adult developmental disorders section of the department of psychiatry at the University of Pennsylvania Health System. He reports that he is a consultant for Shire and is on the speakers' bureau for Eli Lilly and McNeil Pharmaceuticals.

Clinical approach to managing treatment-resistant ADHD

With the foregoing discussion in mind, it is important to approach each patient in a systematic and comprehensive fashion and to reassess the patient's diagnosis. Comorbid conditions such as learning disorders, anxiety and mood disorders, and executive dysfunction (including deficient working memory, organizational skills, and time perception) can reduce treatment efficacy. These require careful consideration by the clinician and will probably necessitate a revision of treatment goals and approaches. Patient and family educational sessions are useful for clarifying new information about the patient's condition, and for placing these findings in a broader context. For instance, the presence of learning disabilities might shift the focus of treatment to school-based interventions. Likewise, the appearance of anxiety or mood disorders, in either the child or the parents, might indicate the need to focus more on intensive family therapy approaches.

Medication nonadherence is a major source of treatment resistance and should be addressed in a nonjudgmental and balanced fashion. If nonadherence is because of ambivalence on the part of the patient and his parents, it is worthwhile to conduct motivational enhancement interviews to determine whether they are ready to accept responsibility for undertaking a medication regimen. It is valuable to find out the precise reasons why the patient and family are not willing to comply with treatment, and to learn about their views of the consequences (both positive and negative) of taking or not taking the prescribed medication.

The primary reason for nonadherence is often the appearance of adverse effects, especially in the face of equivocal clinical results. If this is so, it is vital that the clinician make adjustments to improve the cost-benefit ratio of treatment. This may be achieved by increasing the current dose of medication (to achieve greater symptom control), switching to a different class of medication, combining the current medication with another agent, or stopping medications altogether. More frequent visits to enable closer monitoring of pharmacotherapy may also promote greater adherence.

If initial treatment with a stimulant medication has not been successful, the Texas Children's Medication Algorithm for ADHD (Figure),34 introduced in 1998 and revised in 2004, recommends starting treatment with either methylphenidate(Drug information on methylphenidate) or amphetamine and increasing the dosage to optimal levels as needed. If partial or nonresponse to medication results, a switch to another stimulant medication is advised. If this does not work, atomoxetine(Drug information on atomoxetine) is used in place of a stimulant. If the response is not satisfactory, combining atomoxetine with a stimulant is recommended. Following this, bupropion or a tricyclic antidepressant is substituted for atomoxetine. As a last step, the addition of an a-agonist (guanfacine or clonidine(Drug information on clonidine)) is advised. If there is still no satisfactory clinical response, a consultation with a specialist in ADHD pharmacology may be in order.

Other medication combinations have been beneficial for some patients. For instance, the combination of an SSRI and a stimulant can be quite effective for patients with ADHD and comorbid anxiety disorders, including generalized anxiety disorder, social phobia, and obsessive-compulsive disorder. Atomoxetine is also useful for ADHD patients with these conditions.35 Patients who experience adverse effects with stimulants seem to tolerate modafinil(Drug information on modafinil) quite well, although the absence of FDA approval for ADHD has created an economic barrier for many families who cannot afford to pay out-of-pocket for this medication. Venlafaxine appears to be helpful in adolescents and adults with ADHD and comorbid anxiety and/or depression. With cautious dosing, stimulant medication can be safely added to venlafaxine, although careful cardiovascular monitoring is recommended. Finally, small open-label studies and case series have shown a modest benefit with monoamine oxidase inhibitors, the an- ticholinesterase inhibitor donepezil(Drug information on donepezil), and the combination of stimulant and a-agonist.36

Turning to the issue of inadequate response to psychosocial interventions, one of the most important findings from the MTA study is the strongly negative impact that parental depression has on treatment outcomes. Considering this, along with the fact that many parents of ADHD children have ADHD themselves, it is important that the astute clinician pay attention to how parents are faring. If there is evidence of excess stress or burnout (as evidenced by direct and indirect statements, nonverbal cues, or inconsistent attendance at office visits), it makes sense to schedule a separate session to discuss the parents' issues. Severe parental psychopathology (eg, substance abuse, major mood disorders, psychosis) can be especially difficult to address and might require enlisting other family members to help the individual obtain treatment.

Above all else, it is vital that the clinician maintain respect for the significance of the parent's role in the life of his or her child or adolescent. The vulnerabilities, needs, resources, and capacities of each parent must be taken into consideration whenever a psychosocial intervention is attempted. The demands of family-oriented treatment (eg, completing homework assignments between sessions, changing one's habitual responses to the child's negative behavior, making time, and paying for sessions) should not be overlooked and, when appropriate, genuine appreciation for the parent's dedication and involvement in the process of helping the child who has ADHD should be generously provided.

Attempts must be made to work with the child's educational setting, especially if there are serious conflicts between family members and the school staff. Even the best efforts to assist patient and family cope with ADHD are neutralized by intransigent or antagonistic school personnel, especially the child's teachers. It is especially important to talk directly with school staff to reduce misunderstandings and promote a collaborative approach to help the child succeed in school. When an individualized education program or a Section 504 plan is not being effectively implemented, it is helpful to alert the school, and to offer to meet in person to discuss ways to put needed accommodations into place. As much as possible, the clinician should act as an advocate for the child while maintaining a pragmatic appraisal of the resources of the school and the school district. Unrealistic expectations on the part of the child or family about the capacity of the school to meet every aspect of the child's academic and social needs should be gently but firmly confronted and educational options (including approved private schools or home schooling) should be discussed if family-school conflicts appear insurmountable.

Case Vignette

Tommy's presentation at the office visit suggested that his anxiety about school was extremely high and that he had a depressed mood. Further exploration revealed that he truly felt worse when he was taking the medication, and that his ability and motivation to complete his homework assignments were virtually nonexistent. His medication was switched to atomoxetine, which resulted in moderate improvement in concentration and a marked reduction in anxiety symptoms.

A telephone call to the school led to an immediate reduction in homework and an increase in resource-room time to make up for missing assignments. The school guidance counselor made time to speak to Tommy on a regular basis about his negative views toward school, and over the ensuing month, his attitude began to shift in a more positive direction.

Family therapy sessions were geared toward changing unrealistic parental expectations and anxiety about academics and de-escalating their preoccupations with Tommy's homework in favor of developing more positive interactions with him. During the next few months, Tommy started taking more responsibility for homework and began spending more time socializing with family and friends.

Pages: 1  2  3  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





  • Barkley RA. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract. 2004;10:39-56.
  • Chronis AM, Jones HA, Raggi VL. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Clin Psychol Rev. 2006;26:486-502.
References
1. Barkley RA. Major life activity and health outcomes associated with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2002;63:10-15.
2. Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York: Guilford Press; 2006.
3. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113-131.
4. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry. 1996;37:393-401.
5. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 2002;30:463-475.
6. Barkley RA, Murphy KR, DuPaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsycol Soc. 2002;8:655-672.
7. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004; 45:195-211.
8. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38-45.
9. Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adol Psychiatric Clin N Am. 2000;9:525-540, vii.
10. Murphy K, Barkley RA, Bush T. Young adults with attention-deficit/hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis. 2002;190:147-157.
11. Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;64:3-8.
12. Spencer T. ADHD and comorbidity in childhood. J Clin Psychiatry. 2006;67:27-31.
13. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/ hyperactivity disorder. J Amer Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S-121S.
14. Owens EB, Hinshaw SP, Arnold LE, et al. Which treatment for whom with ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71:540-552.
15. Hinshaw SP. Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work. J Ped Psychol. 2007;32: 664-675.
16. Steele M, Jensen PS, Quinn DP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892-1907.
17. Hechtman L, Abikoff H, Klein RG, et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psycho-social treatment. J Amer Acad Child Adolesc Psychiatry. 2004;43:812-819.
18. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211.
19. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics. 2004;113:e206-e216.
20. Cox DJ, Merkel L, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118:e704-e710.
21. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003;65:3-7.
22. Wilens TE, Faraone SV, Biederman J, Gunwardene S. Does stimulant therapy of attention deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185.
23. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404-e413.
24. Steele M, Weiss M, Swanson J, et al. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methyl-phenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50-e62.
25. Spencer T, Biederman J, Wilens T. Efficacy and tolerability of long-term, open-label, mixed amphetamine sales extended release in adolescents with ADHD. CNS Spectrums. 2005;10:14-21.
26. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children with attention deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
27. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e1-e8.
28. Chronis AM, Jones HA, Raggi VL. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Clin Psychol Rev. 2006;26:486-502.
29. Barkley RA, Guevremont DC, Anastopoulos AD, Fletcher KE. A comparison of three family therapy programs for treating family conflicts in adolescents with attention- deficit hyperactivity disorder. J Consult Clin Psychol. 1992;60:450-462.
30. Barkley RA, Edwards G, Laneri M, et al. The efficacy of problem-solving communication training alone, behavior management training alone, and their combination for parent-adolescent conflict in teenagers with ADHD and ODD. J Consult Clin Psychol. 2001;69:926-941.
31. McCleary L, Ridley T. Parenting adolescents with ADHD: evaluation of a psychoeducation group. Patient Educ Couns. 1999;38:3-10.
32. Raggi VL, Chronis AM. Interventions to address the academic impairment of children and adolescents with ADHD. Clin Child Fam Psychol Rev. 2006;9:85-111.
33. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(suppl 8):38-45.
34. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642-657.
35. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44:915-924.
36. Wagner KD. Management of treatment refractory attention-deficit/hyperactivity disorder in children and adolescents. Psychopharmacol Bull. 2002;36:130-142.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
  • Benefits of CAM Therapies for Dementia
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy